Predictive Oncology Expands The Application Of Its Live-cell Tumor Platform To De-risk Drug Discovery And Accelerate Pipeline Development

Predictive Oncology Inc. has expanded the applications of its AI platform to account for patient heterogeneity and increase the Probability of Technical Success in drug discovery. This addresses the high failure rate in late-stage clinical trials and utilizes the company’s unique assets and resources to introduce patient heterogeneity in the earliest phases of AI-driven drug discovery.